FindTrial
Sign In

Management Status and Prognostic Model Development for Takayasu Arteritis with Pulmonary Artery Involvement in China: A Multicenter Cohort Study

Management Status and Prognostic Model Development for Takayasu Arteritis with Pulmonary Artery Involvement in China: A Multicenter Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108731
Enrollment
Unknown
Registered
2025-09-04
Start date
2025-09-04
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Takyasu Arteritis

Interventions

PTPA group:None
Non-PTPA group:None

Sponsors

State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Takayasu Arteritis: Meeting the modified Ishikawa diagnostic criteria (2019 Sharma revision); 2. Pulmonary Artery Involvement: Confirmed by CTPA or Digital Subtraction Angiography (DSA) with any of the following lesions: (1) Pulmonary artery stenosis/occlusion (involving the main trunk or lobar/segmental branches); (2) Pulmonary artery wall thickening (diastolic thickness >2 mm); (3) Pulmonary artery aneurysm (diameter >1.5 times that of the adjacent vessel). 3. Age Range: 14–70 years. 4. Complete baseline assessment including: Cardiopulmonary function (WHO-FC classification, 6MWD); Laboratory tests (C-Reactive Protein (CRP)/Erythrocyte Sedimentation Rate (ESR), N-terminal pro-B-type Natriuretic Peptide (NT-proBNP)); Right heart catheterization (mean Pulmonary Arterial Pressure (mPAP) =25 mmHg) or echocardiography (Tricuspid Regurgitation Velocity (TRV) >3.4 m/s).

Exclusion criteria

Exclusion criteria: 1. Pulmonary hypertension due to other causes (Group 1/3/4/5) 2. Active tuberculosis or fungal infection 3. Congenital pulmonary vascular malformations 4. Active malignancy without curative treatment 5. Overlap syndromes: Meeting diagnostic criteria for other systemic vasculitides (e.g., Behçet’s disease) or connective tissue diseases (e.g., systemic sclerosis) 6. Insufficient data: Missing >20% of key follow-up indicators (e.g., right heart catheterization, CTPA) 7. Special populations: Pregnant or lactating women 8. Participation in other interventional clinical trials within 3 months

Design outcomes

Primary

MeasureTime frame
Event-free Survival;—

Secondary

MeasureTime frame
Right heart catheterization;Exercise Tolerance;Imaging Parameters;Riht heart function;Serological Markers;—

Countries

China

Contacts

Public ContactChangming Xiong

State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, CAMS & PUMC, Beijing, 100037, China

zengqixian@fuwaihospital.org+86 158 1004 0405

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026